Antisense And RNAi Therapeutics Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Application, By Route of Administration, By Region and Competition, 2020-2030F

Description

The Global Antisense And RNAi Therapeutics Market, valued at USD 5.20 Billion in 2024, is projected to experience a CAGR of 19.19% to reach USD 14.91 Billion by 2030. Antisense and RNAi therapeutics represent a molecular medicine class that precisely modulates gene expression by either inhibiting protein production via antisense oligonucleotides or degrading messenger RNA through RNA interference, offering targeted interventions for various diseases. The market's expansion is fundamentally driven by the rising global incidence of genetic and chronic disorders, alongside a burgeoning understanding of intricate molecular disease mechanisms enabling highly specific therapeutic design. Growing investments in research and development further propel this growth by expanding the addressable therapeutic landscape for conditions with limited treatment options.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 5.20 Billion
Market Size 2030	USD 14.91 Billion
CAGR 2025-2030	19.19%
Fastest Growing Segment	RNA Interference
Largest Market	North America

Key Market Drivers

The global Antisense and RNAi Therapeutics Market is significantly influenced by the increasing burden of genetic and chronic diseases, which establishes a profound unmet medical need for innovative treatments. These therapies offer precise modulation of gene expression, addressing the root causes of many disorders where conventional treatments fall short. The substantial patient population suffering from these conditions drives consistent demand for novel therapeutic avenues.

Key Market Challenges

The persistent complexity in achieving efficient and precisely targeted *in vivo* delivery of nucleic acid-based molecules to specific cells and tissues directly impedes the growth of the Global Antisense and RNAi Therapeutics Market. This challenge arises from the inherent properties of these molecules, such as their size, negative charge, and susceptibility to enzymatic degradation, which hinder their ability to cross biological barriers and reach their intracellular targets in sufficient concentrations. Consequently, the development of novel therapies is prolonged due to the extensive research required for suitable delivery vehicles, increasing overall development costs and time to market.

Key Market Trends

Antisense and RNAi therapeutics are increasingly expanding into broader therapeutic areas beyond rare diseases. This strategic diversification involves targeting more prevalent chronic conditions such as cardiovascular, metabolic, and neurological disorders, indicating a growing confidence in the technology's applicability to larger patient populations.

Key Market Players

Olix Pharmaceuticals, Inc.
GSK plc
Sanofi Aventis S.A.
Alnylam Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Benitec Biopharma Inc
Silence Therapeutics Inc.
Arbutus Biopharma Inc.
Sarepta Therapeutics Inc.
Percheron Therapeutics Limited.

Report Scope:

In this report, the Global Antisense And RNAi Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antisense And RNAi Therapeutics Market, By Technology:

RNA Interference
Antisense RNA

Antisense And RNAi Therapeutics Market, By Route of Administration:

Intravenous Injections
Intrathecal Injections
Subcutaneous Injections
Other

Antisense And RNAi Therapeutics Market, By Application:

Ocular
Cardiometabolic & Renal Disorders
Cancer
Respiratory Disorders
Skin Diseases
Neurodegenerative Disorders
Genetic Disorders
Infectious Diseases

Antisense And RNAi Therapeutics Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Antisense And RNAi Therapeutics Market.

Available Customizations:

Global Antisense And RNAi Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antisense And RNAi Therapeutics Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Technology (RNA Interference, Antisense RNA)
- 5.2.2. By Route of Administration (Intravenous Injections, Intrathecal Injections, Subcutaneous Injections, Other)
- 5.2.3. By Application (Ocular, Cardiometabolic & Renal Disorders, Cancer, Respiratory Disorders, Skin Diseases, Neurodegenerative Disorders, Genetic Disorders, Infectious Diseases)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
5.3. Market Map

6. North America Antisense And RNAi Therapeutics Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Technology
- 6.2.2. By Route of Administration
- 6.2.3. By Application
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Antisense And RNAi Therapeutics Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Technology
    - 6.3.1.2.2. By Route of Administration
    - 6.3.1.2.3. By Application
- 6.3.2. Canada Antisense And RNAi Therapeutics Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Technology
    - 6.3.2.2.2. By Route of Administration
    - 6.3.2.2.3. By Application
- 6.3.3. Mexico Antisense And RNAi Therapeutics Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Technology
    - 6.3.3.2.2. By Route of Administration
    - 6.3.3.2.3. By Application

7. Europe Antisense And RNAi Therapeutics Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Technology
- 7.2.2. By Route of Administration
- 7.2.3. By Application
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Antisense And RNAi Therapeutics Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Technology
    - 7.3.1.2.2. By Route of Administration
    - 7.3.1.2.3. By Application
- 7.3.2. France Antisense And RNAi Therapeutics Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Technology
    - 7.3.2.2.2. By Route of Administration
    - 7.3.2.2.3. By Application
- 7.3.3. United Kingdom Antisense And RNAi Therapeutics Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Technology
    - 7.3.3.2.2. By Route of Administration
    - 7.3.3.2.3. By Application
- 7.3.4. Italy Antisense And RNAi Therapeutics Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Technology
    - 7.3.4.2.2. By Route of Administration
    - 7.3.4.2.3. By Application
- 7.3.5. Spain Antisense And RNAi Therapeutics Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Technology
    - 7.3.5.2.2. By Route of Administration
    - 7.3.5.2.3. By Application

8. Asia Pacific Antisense And RNAi Therapeutics Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Technology
- 8.2.2. By Route of Administration
- 8.2.3. By Application
- 8.2.4. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Antisense And RNAi Therapeutics Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Technology
    - 8.3.1.2.2. By Route of Administration
    - 8.3.1.2.3. By Application
- 8.3.2. India Antisense And RNAi Therapeutics Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Technology
    - 8.3.2.2.2. By Route of Administration
    - 8.3.2.2.3. By Application
- 8.3.3. Japan Antisense And RNAi Therapeutics Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Technology
    - 8.3.3.2.2. By Route of Administration
    - 8.3.3.2.3. By Application
- 8.3.4. South Korea Antisense And RNAi Therapeutics Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Technology
    - 8.3.4.2.2. By Route of Administration
    - 8.3.4.2.3. By Application
- 8.3.5. Australia Antisense And RNAi Therapeutics Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Technology
    - 8.3.5.2.2. By Route of Administration
    - 8.3.5.2.3. By Application

9. Middle East & Africa Antisense And RNAi Therapeutics Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Technology
- 9.2.2. By Route of Administration
- 9.2.3. By Application
- 9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Antisense And RNAi Therapeutics Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Technology
    - 9.3.1.2.2. By Route of Administration
    - 9.3.1.2.3. By Application
- 9.3.2. UAE Antisense And RNAi Therapeutics Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Technology
    - 9.3.2.2.2. By Route of Administration
    - 9.3.2.2.3. By Application
- 9.3.3. South Africa Antisense And RNAi Therapeutics Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Technology
    - 9.3.3.2.2. By Route of Administration
    - 9.3.3.2.3. By Application

10. South America Antisense And RNAi Therapeutics Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Technology
- 10.2.2. By Route of Administration
- 10.2.3. By Application
- 10.2.4. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Antisense And RNAi Therapeutics Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Technology
    - 10.3.1.2.2. By Route of Administration
    - 10.3.1.2.3. By Application
- 10.3.2. Colombia Antisense And RNAi Therapeutics Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Technology
    - 10.3.2.2.2. By Route of Administration
    - 10.3.2.2.3. By Application
- 10.3.3. Argentina Antisense And RNAi Therapeutics Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Technology
    - 10.3.3.2.2. By Route of Administration
    - 10.3.3.2.3. By Application

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Antisense And RNAi Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Olix Pharmaceuticals, Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. GSK plc
15.3. Sanofi Aventis S.A.
15.4. Alnylam Pharmaceuticals, Inc.
15.5. Ionis Pharmaceuticals, Inc.
15.6. Benitec Biopharma Inc
15.7. Silence Therapeutics Inc.
15.8. Arbutus Biopharma Inc.
15.9. Sarepta Therapeutics Inc.
15.10. Percheron Therapeutics Limited.